NCT06096090View on ClinicalTrials.gov

Phase II Clinical Trial of Interleukin-2 in AD

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Alzheimer Disease
Interventions
DRUG

Interleukin-2

Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells

DRUG

Placebo

Placebo administration

Trial Locations (1)

77030

RECRUITING

Houston Methodist Research Institute, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER